




PHARMACEUTICAL 2019

DURECT CORP
Rank 112 of 363





PHARMACEUTICAL 2019

DURECT CORP
 Rank 112 of 363



The relative strengths and weaknesses of DURECT CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DURECT CORP compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 38% points. The greatest weakness of DURECT CORP is the variable Research and Development, reducing the Economic Capital Ratio by 34% points.

The company's Economic Capital Ratio, given in the ranking table, is 165%, being 128% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	41,740
Cost of Goods Sold	4,263
Intangible Assets	6,399
Liabilities, Current	7,662
Liabilities, Non-Current	0
Other Assets	1,255
Other Compr. Net Income	1.0
Other Expenses	0
Other Liabilities	0
Other Net Income	-1,703
Other Revenues	18,564
Property and Equipment	605
Research and Development	25,501
Selling, General and Administrative Expense	12,419

Output Variable	Value in 1000 USD
Assets	49,999
Liabilities	7,662
Expenses	42,183
Revenues	18,564
Stockholders Equity	42,337
Net Income	-25,322
Comprehensive Net Income	-25,322
Economic Capital Ratio	165%